Liminatus Pharma Plans Phase 1 Trial for Next-Gen CD47 Cancer Antibody IBA101
LIMN sits 18% above its 52-week low of $0.21 on light trading volume (0.1× avg).
Summary
Liminatus Pharma announced its plans to initiate a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking monoclonal antibody. This drug candidate is designed to enhance macrophage-mediated tumor clearance by targeting the "don't-eat-me" signal on cancer cells, with an initial focus on lung cancer. For a micro-cap biotech company, advancing a novel therapeutic into clinical development is a material pipeline progression event, signaling potential future value. The planned study will first evaluate monotherapy safety and pharmacokinetics, followed by combination cohorts with PD-1/PD-L1 therapies. Investors will now watch for the actual commencement of the trial and initial data readouts.
At the time of this announcement, LIMN was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $0.21 to $33.66. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.